shutterstock_1258200124-marcos__silva
Marcos Silva / Shutterstock.com
6 August 2020Big PharmaSarah Morgan

KIPA hires former Decode Genetics director

IP boutique  KIPA has strengthened its team with the addition of Iceland-based patent attorney Thorlakur Jonsson.

Jonsson, who joins from IP firm  Arnason Faktor, will handle new cases relating to chemistry, biotech and pharmaceuticals.

He advises clients patent-related matters, including patent drafting and prosecution, opposition and appeal before the European Patent Office, patentability assessments, infringement and freedom to operate and validity analyses.

Jonsson previously served as director of IP at  Decode Genetics, an Iceland-based human genetics company, and he has more than 25 years of research and development experience in academic and industrial settings.

“I am very pleased to join the strong IP team at KIPA and hope that my experience in the chemistry and biotechnology areas will be of value to KIPA's current and future clients,” he said.

Currently, Jonsson is a member of the European Patent Institute’s council and biotechnology committee.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.


More on this story

Big Pharma
16 July 2020   A US federal court has thrown out an appeal from Ono Pharmaceutical and a Nobel Prize-winning immunologist, in a dispute over who made groundbreaking discoveries in cancer therapy.
Americas
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.

More on this story

Big Pharma
16 July 2020   A US federal court has thrown out an appeal from Ono Pharmaceutical and a Nobel Prize-winning immunologist, in a dispute over who made groundbreaking discoveries in cancer therapy.
Americas
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.